(Via fiercebiotech.com) Atlas Venture, Novartis Venture Fund, GlaxoSmithKline’s and Astellas venture management have all joined forces in raising £20 million in capital to back Bicycle Therapeutics. Based in Cambridge UK, Bicycle Therapeutics describes itself as a ‘next generation biothearpeutics company’. The technology being developed by the company has wide ranging potential applications, from oncology to ophthalmology.

Read the full story here and Bicycle Therapeutic’s press release here.